ARCT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
3.0M
+43.6%
2.1M
-71.4%
7.2M
-58.0%
17.2M
-39.4%
28.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
3.0M
+43.6%
2.1M
-71.4%
7.2M
-58.0%
17.2M
-39.4%
28.3M
Operating Expenses
28.5M
-8.0%
31.0M
-19.5%
38.5M
+14.4%
33.7M
-15.7%
39.9M
R&D
17.5M
-18.6%
21.5M
-12.0%
24.5M
+5.2%
23.3M
-21.3%
29.6M
SG&A
11.0M
+16.1%
9.5M
-32.5%
14.0M
+34.9%
10.4M
+0.6%
10.3M
Operating Income
-25545000
+11.7%
-28931000
+7.6%
-31307000
-89.6%
-16512000
-42.1%
-11616000
EBITDA
-24902000
+11.9%
-28273000
+7.7%
-30625000
-94.5%
-15749000
-45.3%
-10837000
Net Income
-23785000
+11.8%
-26964000
+7.3%
-29079000
-116.2%
-13448000
-46.5%
-9180000
EPS (Basic)
$-0.84
+11.6%
$-0.95
+7.8%
$-1.03
-110.2%
$-0.49
-44.1%
$-0.34
EPS (Diluted)
$-0.84
+11.6%
$-0.95
+7.8%
$-1.03
-110.2%
$-0.49
-44.1%
$-0.34
Shares (Diluted)
28.4M
+0.0%
28.4M
+1.1%
28.1M
+3.4%
27.2M
+0.2%
27.1M
Arcturus Therapeutics (ARCT) โ€” Financials